Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Areeya Faosap loads blood culture bottles at the MORU Microbiology BSL2 Melioid lab in Ubon Ratchathani © 2019 MORU. Photographer: Gerhard Jørén.
Areeya Faosap loads blood culture bottles at the MORU Microbiology BSL2 Melioid lab in Ubon Ratchathani
  • Estimated that the global burden of melioisosis is 4.6 million disability-adjusted life-years (DALYs) pear year (Lancet Infect Dis. 2019 Aug;19(8):892-902)
  • Estimated that there are 165,000 human melioidosis cases per year worldwide, of which 89,000 die. (Nat Microbiol. 2016 Jan 1;1(1))
  • Led and supported a large series of publications describing current burden and challenges of melioidosis from melioidosis network in each country (21 publications; Trop Med Infect Dis. 2018;3(2):38)
  • Showed feasibility and initial outcomes of a multifaceted prevention programme of melioidosis in pilot groups of diabetic patients (PLoS Negl Trop Dis. 2018;12(9):e0006765)
  • Developed a rapid immunochromatography test (ICT) for POC detection of IgG antibodies to Hcp1 (J Clin Microbiol. 2018;56(8)).
  • Demonstrated that Burkholderia pseudomallei undergo phenotypic adaptation at the proteomic and transcriptomic levels in response to an increase in growth temperature (Paksanont S et al, Sci Rep. 2018;8(1):9167).
  • Reported that B. pseudomallei is commonly misidentified as Acinetobacter spp. and other bacteria even in the laboratory of a provincial hospital in northern Thailand ( Trans R Soc Trop Med Hyg. 2019 Jan 1;113(1):48-51).